To use all functions of this page, please activate cookies in your browser.
My watch list
my.bionity.com
my.bionity.com
With an accout for my.bionity.com you can always see everything at a glance – and you can configure your own website and individual newsletter.
- My watch list
- My saved searches
- My saved topics
- My newsletter
22 Current news of Sanofi Pasteur
rss
CureVac, Sanofi Pasteur and In-Cell-Art Collaborate on a $33.1 Million Project Co-Funded by the U.S. Defense Advanced Research Projects Agency
4-year collaboration in field of prophylactic and therapeutic vaccines for infectious diseases
16-11-2011
CureVac GmbH announced the signing of several agreements with Sanofi Pasteur S.A., the vaccines division of Sanofi. Under these agreements, CureVac and Sanofi Pasteur will further develop and apply CureVac’s proprietary RNActive® technology platform to the development of vaccines against ...
Leukocare and Sanofi Pasteur sign cooperation agreement for vaccine stabilization
27-07-2011
Leukocare AG announced the signing of a cooperation agreement with Sanofi Pasteur, the vaccines division of Sanofi. As part of this cooperation, Sanofi Pasteur will explore Leukocare ’s SPS platform technology to enhance the shelf-life of selected vaccine formulations.Leukocare’s Stabilizing ...
Pieris Signs Broad Collaboration with Sanofi-Aventis and Sanofi Pasteur to Develop Anticalin Therapeutics
30-09-2010
Pieris AG announced the signature of a collaboration and license agreement with both Sanofi-Aventis and Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, under which Pieris will apply its proprietary Anticalin technology to discover novel Anticalin drugs against multiple ...
Crucell Reaches Agreement with Sanofi Pasteur on Programs in the Field of Paediatric and Respiratory Vaccines
09-07-2010
Crucell N.V. announced that Crucell and sanofi pasteur reached an agreement on a series of transactions to restructure their long standing partnership. Crucell will waive its right to terminate an existing license agreement between Crucell Switzerland and sanofi pasteur's subsidiary Shantha ...
Sanofi Pasteur Partners With Vivalis For The Discovery of Human Monoclonal Antibodies Against Infectious Diseases
10-06-2010
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced the signature with Vivalis of a commercial license and collaboration agreement for the discovery and development of fully human monoclonal antibodies against several infectious diseases. Under the terms of the ...
Sanofi Pasteur Partners with KaloBios on Novel Biologic for the Prevention and Treatment of Pseudomonas aeruginosa Infections
13-01-2010
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced an agreement with KaloBios Pharmaceuticals for the development of a Humaneered™ antibody fragment to both treat and prevent Pseudomonas aeruginosa (Pa) infections. Under the terms of the agreement, Sanofi Pasteur ...
U.S. FDA Licenses Sanofi Pasteur's Pandemic Influenza Vaccine
21-09-2009
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental biologics license application (sBLA) for licensure of its Influenza A (H1N1) 2009 Monovalent Vaccine. The U.S. licensed ...
Sanofi Pasteur and Butantan Institute to Provide A(H1N1) Vaccine to Brazilian Government
Initial supply of 18 million doses of A(H1N1) influenza vaccine
09-09-2009
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced it has signed an agreement with Butantan Institute for the production and supply of a vaccine against the novel A(H1N1) influenza virus for the Brazilian Government. This contract was announced during a state visit to ...
Shantha Biotechnics awarded large vaccine contracts by United Nations agency
Shantha awarded 2010-2012 contracts for pentavalent vaccine SHAN5™ (DTP, HiB, Hep.B)
03-09-2009
Sanofi Pasteur, the vaccines division of sanofi-aventis Group, announced that Shantha Biotechnics was awarded contracts by a United Nations agency for supplies of pentavalent vaccine SHAN5™ (combination vaccine of Diphtheria, Pertussis, Tetanus, Haemophilus influenza B, and Hepatitis B). The ...
Sanofi Pasteur submits supplemental application for A(H1N1) pandemic vaccine to U.S. FDA
11-08-2009
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, announced the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine. Responding to recent recommendations by the FDA, the ...
Netmeeting
